Increased Focus Being Placed On Using “Real World Evidence” In Regulatory Decision Making
In This Issue
Jobs For Epidemiologists Have Increased Several Fold The traditional pathway to getting new drugs approved has been through the conduct of randomized control trials (RCTs). More recently, an intensifying focus on using nonclinical trial, real world data (RWD) and real world evidence (RWE) as part of a pathway to drug licensure is creating new possibilities and raising new challenges for all parties
involved--- regulators, scientists, and drug and insurance companies. At the same time, this new pragmatism about observational data is creating a huge boost for epidemiologists already inside biopharma and is creating new job opportunities for others. - Real World continues on page 2
Keynote Speaker At ACE Meeting Chronicles Thirteen Infectious Disease Threats Seen Under Five Presidents The Infectious Disease Challenge Called “Perpetual” “If history has taught us anything, it is that the new administration is likely to experience at least one infectious disease crisis of significance.” So spoke Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID), and keynote speaker at the recent American College of Epidemiology meeting in New Orleans.
October 2017
- Fauci cont'd on page 7 •
Volume Thirty Eight
-5WHO Sounds Alarm on NonCommunicable Diseases
-8Notes on People
less than 13 emerging infectious diseases or challenges since the Reagan administration in 1981-89 and during four subsequent Presidential administrations since his taking over the helm of the NIAID in 1984. He outlined the problems and the lessons learned during this talk at ACE. The challenges have only increased over the years.
Fauci chronicled the appearance of no
-3NAS Calls for Action to Address Bullying
•
Number Ten
-12Marketplace